This product directly acts on the endogenous fibrinolytic system to catalyze the cleavage of plasminogen into plasmin, which can not only degrade fibrin clots, but also degrade fibrinogen, coagulation factor V and coagulation factor VIII in the blood circulation, thereby exerting a thrombolytic effect. This product has a fast onset and good effect on newly formed thrombi. This product can also increase vascular ADP enzyme activity, inhibit ADP-induced platelet aggregation, and prevent thrombosis. After intravenous infusion of this product, the activity of plasmin in the patient's body is significantly increased; a few hours after stopping the drug, the plasmin activity returns to the original level, but the decrease in plasma fibrin or fibrinogen levels and the increase in their degradation products can last for 12-24 hours. This product shows a significant correlation between the thrombolytic effect and the drug dose and the time window of administration.

It can interact with the lipoprotein membrane of sperm cells, change the permeability of sperm cells, and thus kill sperm or make them lose their motility. It also has bactericidal and anti-inflammatory functions.

No specific description of pharmacological effects is given from the above information

Extract from the above information

Extracting pharmacological effects from the above information